Information  X 
Enter a valid email address

GAN PLC (GAN)

  Print      Mail a friend

Thursday 10 January, 2019

GAN PLC

Major US Expansion with the FanDuel Group

RNS Number : 6753M
GAN PLC
10 January 2019
 

 

 

LONDON STOCK EXCHANGE (LSE): GAN | IRISH STOCK EXCHANGE (ISE): GAME

 

GAN Announces Major US Expansion with the FanDuel Group

 

London & Dublin ed States, today announced the signing of a material long-term deal with the FanDuel Group ("FDG") to be FDG's Platform for rapid deployment of Internet casino, and account services for Internet sports betting in Pennsylvania (pop. 13M) and West Virginia (pop. 1.8M), in addition to the existing services provided since 2013 by GAN to FDG in the State of New Jersey (pop. 9M).

 

This expanded contract represents a material increase in the value of the partnership to GAN across revenue share, professional services and patent licensing fees.

 

As part of the contract expansion FDG has agreed to license GAN's US Patent. GAN's patented technology allows land-based casino patrons enrolled in on-property loyalty programs to link existing loyalty cards to Internet gambling accounts and receive loyalty points in exchange for online gambling. Linking of patrons' loyalty cards is proven to greatly enhance online engagement by US casino patrons as well as substantially increasing lifetime value realized online through increased monetization and retention. Management believes that the recognition of GAN's US Patent significantly underpins GAN's intangible asset value and could potentially lead to further client partnerships and US Patent licensing revenue opportunities

 

Deal Highlights

 

·     Second client in the State of Pennsylvania (FanDuel Group) in addition to Parx Casino

·     Two additional US States (PA, WV) represent a combined population of approximately 14.8M

·     Licensure of strategic US Patent for linking US casino patrons' loyalty cards to their online gambling accounts, greatly enhancing GAN's IP licensing & enforcement program

·     Initial rapid deployment of FanDuel into both West Virginia and Pennsylvania

·     Five-year contract term extension commencing in 2019 and ending in 2024

 

Management Commentary

 

Dermot Smurfit, CEO of GAN commented:

 

"The contract extension combined with US Patent licensing represents a significant milestone in GAN's US evolution and reinforces our view that in the heavily regulated US online gambling market, effective and compliant 'platforms' are a premium component of the supply chain rather than a commodity. GAN is therefore very well placed to capitalize on the growth in US online gambling markets in terms of new operator clients, new States and underlying growth momentum."

 

About GAN Plc

GAN is a leading business-to-business ("B2B") supplier of internet gambling software-as-a-service solutions ("SaaS") to the US land-based casino industry. The Company has developed a proprietary internet gambling enterprise software system, GameSTACK™, which it licenses principally to land-based US casino operators as a turnkey technology solution for regulated real-money internet gambling, encompassing internet gaming, internet sports gaming and virtual Simulated Gaming.

 

GAN is listed on the London Stock Exchange (LSE: GAN) and on the Irish Stock Exchange (ISE: GAME).

 

For more information please visit www.GAN.com.

 



 

For further information please contact:

 

GAN

US Investors: The Equity Group

Dermot Smurfit

Adam Prior

Chief Executive Officer

[email protected]

+44 (0) 20 7292 6262

212.371.8660

[email protected]

 

 

UK & Ireland Investors: Walbrook PR

 

Paul Cornelius

 

[email protected]

 

+44 20 7933 8780

 

 

Davy (Nominated Adviser, ESM Adviser and Joint Broker)

 

 

John Frain / Barry Murphy

 

 

+353 1 679 6363

 

 

 

Liberum (Joint Broker)

 

 

Neil Patel / Cameron Duncan

 

 

+44 (0) 20 3100 2000

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
CNTBLMRTMBMMBRL

a d v e r t i s e m e n t